NEW YORK - Nanowear has received clearance from the U.S. Food and Drug Administration for a remote cardiac monitoring undergarment called SimplECG. “The FDA’s decision not only positions us for commercial opportunities in remote cardiac monitoring, but more importantly, it provides accreditation of the company’s one-of-a-kind, cloth-based sensor technology as medical-grade,” said Venk Varadan, Nanowear CEO and co-founder, in a statement. This is the first step and foundation of what the company believes to be an extensive array of applications for its nanosensor technology, including numerous other electrical, biometric and biochemical signals that can be measured directly from the skin without conductive gels, adhesives or skin preparation. “The market of applications for healthcare alone is a multi-billion-dollar opportunity, but as we look beyond to consumer, industrial, clinical research, military and public sector applications, the addressable market expands exponentially,” said Varadan. Having spent the last two years focused solely on product development and the regulatory process, Nanowear will now focus its near-term efforts on product commercialization, strategic partnerships and continued development of complementary products and applications for chronic disease states.
You are here: / / Nanowear receives green light from FDA for cardiac monitoring undergarment